Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02429804 · ClinicalTrials.gov registry record · Phase 1
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
A Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02429804: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT02429804 is a Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02429804, a Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This pilot clinical trial studies combined fluorine F 18 sodium fluoride (NaF)/ fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) in measuring response to a drug, radium Ra 223 dichloride (Ra-223), in treating patients with prostate cancer that has not responded to hormone therapy and has spread to other parts of the body. Combining NaF/FDG in a simultaneous PET/MRI scan may help doctors accurately measure how well patients respond to treatment with radium Ra 223 dichloride.
Interventions
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Positron Emission Tomography
- PROCEDURE Contrast-enhanced Magnetic Resonance Imaging
- DRUG Fludeoxyglucose F-18
- DRUG Fluorine F 18 Sodium Fluoride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-05-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02429804
The ClinicalTrials.gov registry entry for NCT02429804 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT02429804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02429804 about?
NCT02429804 is a clinical study titled "NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer". This pilot clinical trial studies combined fluorine F 18 sodium fluoride (NaF)/ fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) in measuring response to a drug, radium Ra 223 dichloride (Ra-223), in treating patients with prostate cancer that has no...
What is the current status of trial NCT02429804?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2015-04. Estimated completion is 2017-05-15.
What interventions are being tested in trial NCT02429804?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PROCEDURE), Contrast-enhanced Magnetic Resonance Imaging (PROCEDURE), Fludeoxyglucose F-18 (DRUG), Fluorine F 18 Sodium Fluoride (DRUG).
Who is sponsoring clinical trial NCT02429804?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.